PMGC Holdings Inc.(ELAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 6 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ELAB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PMGC Holdings Inc. (ELAB), a Healthcare sector company. ELAB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 6 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), PMGC Holdings Inc. reports quarterly revenue of $682.0K, net income of $-5.0M, free cash flow of $-3.3M. Top institutional holders of ELAB by reported 13-F value include JANE STREET GROUP,, MORGAN STANLEY, Schonfeld Strategic Advisors, based on the most recent SEC filings. ELAB trades on the Nasdaq exchange and files with the SEC under CIK 1840563. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PMGC Holdings Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$682.0K
Net Income
Q1 2026
$-5.0M
Free Cash Flow
Q1 2026
$-3.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-24.0% YoYEPS (Diluted)
Total Assets
+43.1% YoYOp. Cash Flow
-8.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $590.1K | — | $1.7M +123.5% | $766.3K |
| Net Income | $-7.7M -24.0% | $-6.2M -45.2% | $-4.3M -138.9% | $-1.8M |
| EPS (Diluted) | — | — | $-0.40 -111.6% | $-0.19 |
| Total Assets | $12.9M +43.1% | $9.0M +73.3% | $5.2M +174.3% | $1.9M |
| Operating Cash Flow | $-5.9M -8.1% | $-5.5M -20.4% | $-4.6M -187.3% | $-1.6M |
AI Insight: ELAB Financial Trends
ELAB burns cash with accelerating losses and zero revenue visibility; equity base eroding despite debt absence.
• Net loss widened to $5M in Q1 2026 from $1M in Q2 2025; operating cash outflow tripled to $3M.
• Revenue essentially flat or absent across last six quarters; Q1 2026 shows $1M but Q4 2025 was $0M.
• Equity swung from $9M (Q2 2025) to $13M (Q1 2026) despite mounting losses; suggests capital raises masking burn.
⚠ Cash burn accelerated sharply in Q1 2026; runway unclear without disclosed cash position or funding plan.
⚠ No operating income, revenue, or operating cash flow disclosed for Q4 2024–Q3 2025; data gaps obscure true trajectory.
AI Insight: ELAB Ratio Trends
PMGC is deeply unprofitable with deteriorating returns; ROE collapsed to -157.6% in Q1 2026, the worst quarter in the dataset.
• ROE worsened from -24.9% in Q2 2025 to -157.6% in Q1 2026, signaling accelerating losses and shareholder value destruction.
• ROA has remained consistently negative across all periods, ranging from -24.0% to -92.7%, indicating persistent operational losses.
• Q3 2024 alone posted positive ROIC of 51.9%; all other quarters with available data show negative or missing returns.
⚠ Q1 2026 ROE of -157.6% represents a 5.3pp deterioration from Q4 2025 (-152.2%), suggesting worsening profitability trends.
⚠ No operating margin or net profit margin data available; opacity on operational performance limits deeper analysis.
Get alerted when ELAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PMGC Holdings Inc. including:
Top Institutional Holders of ELAB
JANE STREET GROUP, LLC
$189.2K31,594 shMORGAN STANLEY
$89.8K15,000 shSchonfeld Strategic Advisors LLC
$88.7K14,800 shIFP Advisors, Inc
$12.0K2,000 shUBS Group AG
$7.8K1,302 shTower Research Capital LLC (TRC)
$773.00129 sh
| Fund | Value | Shares |
|---|---|---|
| JANE STREET GROUP, LLC | $189.2K | 31,594 |
| MORGAN STANLEY | $89.8K | 15,000 |
| Schonfeld Strategic Advisors LLC | $88.7K | 14,800 |
| IFP Advisors, Inc | $12.0K | 2,000 |
| UBS Group AG | $7.8K | 1,302 |
| Tower Research Capital LLC (TRC) | $773.00 | 129 |
More Healthcare Companies
View all Healthcare →Put ELAB on your watchlist
Track score changes the day PMGC Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ELAB a good stock to buy?
13F Pro's AI-powered analysis of PMGC Holdings Inc. (ELAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELAB are available on the ELAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ELAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PMGC Holdings Inc.'s investment landscape.